OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, F...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

SICC Innvierte, a vehicle managed by CDT...

by CDTI Innovación

With a target size of €250 million, the fund aims to complete betwee...

Photos Stream